经导管主动脉瓣植入术(TAVI)中的脑栓塞保护:4091例患者的汇总分析

IF 3.1 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Mahmoud Balata, Mohamed Ibrahim Gbreel, Mohamed Hamouda Elkasaby, Ahmed Samy Badran, Marwa Hassan, Ralf Westenfeld, Roman Pfister, Sebastian Zimmer, Marc Ulrich Becher, Georg Nickenig, Atsushi Sugiura
{"title":"经导管主动脉瓣植入术(TAVI)中的脑栓塞保护:4091例患者的汇总分析","authors":"Mahmoud Balata, Mohamed Ibrahim Gbreel, Mohamed Hamouda Elkasaby, Ahmed Samy Badran, Marwa Hassan, Ralf Westenfeld, Roman Pfister, Sebastian Zimmer, Marc Ulrich Becher, Georg Nickenig, Atsushi Sugiura","doi":"10.1007/s12928-025-01128-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Transcatheter aortic valve implantation (TAVI) is increasingly used for severe aortic stenosis, but debris embolization during the procedure can lead to strokes, impacting survival and quality of life. The role of cerebral embolic protection devices (CEPDs) in mitigating stroke risk remains debated. We aim to evaluate the impact of CEPDs on the risk of stroke and neurocognitive outcomes after TAVI.</p><p><strong>Methods: </strong>Six databases (PubMed, Scopus, Web of Science, Cochrane, Embase, and Ovid) were searched until 20 January 2023. Original randomized controlled trials (RCTs) were only included and critically appraised using the Cochrane risk of bias (ROB) tool.</p><p><strong>Results: </strong>Seven RCTs (4091 patients) were analyzed. CEPDs significantly reduced the risk of disabling stroke within 2-5 days post-TAVI (relative risk = 0.455, 95% CI: [0.214, 0.967]; p = 0.041). However, there was no significant difference in disabling stroke risk between the two groups at the 30-day follow-up (relative risk = 1.295, 95% CI: [0.373, 4.493]; p = 0.684). No significant differences were observed in non-disabling or overall stroke rates at 2-5 days, 30 days, or 90 days. Additionally, CEPDs did not significantly affect risks of life-threatening bleeding, major vascular complications, mortality, or acute kidney injury.</p><p><strong>Conclusion: </strong>CEPDs are effective in reducing disabling stroke risk in the immediate post-TAVI period (2-5 days) but did not significantly affect the rates of non-disabling stroke, overall stroke, or disabling stroke after 30 days when compared to non-CEPD use. These findings suggest that CEPDs may offer short-term neuroprotection.</p>","PeriodicalId":9439,"journal":{"name":"Cardiovascular Intervention and Therapeutics","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cerebral embolic protection in transcatheter aortic valve implantation (TAVI): a pooled analysis of 4091 patients.\",\"authors\":\"Mahmoud Balata, Mohamed Ibrahim Gbreel, Mohamed Hamouda Elkasaby, Ahmed Samy Badran, Marwa Hassan, Ralf Westenfeld, Roman Pfister, Sebastian Zimmer, Marc Ulrich Becher, Georg Nickenig, Atsushi Sugiura\",\"doi\":\"10.1007/s12928-025-01128-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Transcatheter aortic valve implantation (TAVI) is increasingly used for severe aortic stenosis, but debris embolization during the procedure can lead to strokes, impacting survival and quality of life. The role of cerebral embolic protection devices (CEPDs) in mitigating stroke risk remains debated. We aim to evaluate the impact of CEPDs on the risk of stroke and neurocognitive outcomes after TAVI.</p><p><strong>Methods: </strong>Six databases (PubMed, Scopus, Web of Science, Cochrane, Embase, and Ovid) were searched until 20 January 2023. Original randomized controlled trials (RCTs) were only included and critically appraised using the Cochrane risk of bias (ROB) tool.</p><p><strong>Results: </strong>Seven RCTs (4091 patients) were analyzed. CEPDs significantly reduced the risk of disabling stroke within 2-5 days post-TAVI (relative risk = 0.455, 95% CI: [0.214, 0.967]; p = 0.041). However, there was no significant difference in disabling stroke risk between the two groups at the 30-day follow-up (relative risk = 1.295, 95% CI: [0.373, 4.493]; p = 0.684). No significant differences were observed in non-disabling or overall stroke rates at 2-5 days, 30 days, or 90 days. Additionally, CEPDs did not significantly affect risks of life-threatening bleeding, major vascular complications, mortality, or acute kidney injury.</p><p><strong>Conclusion: </strong>CEPDs are effective in reducing disabling stroke risk in the immediate post-TAVI period (2-5 days) but did not significantly affect the rates of non-disabling stroke, overall stroke, or disabling stroke after 30 days when compared to non-CEPD use. These findings suggest that CEPDs may offer short-term neuroprotection.</p>\",\"PeriodicalId\":9439,\"journal\":{\"name\":\"Cardiovascular Intervention and Therapeutics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-05-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Intervention and Therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12928-025-01128-3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Intervention and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12928-025-01128-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景:经导管主动脉瓣植入术(TAVI)越来越多地用于严重主动脉瓣狭窄,但手术过程中的碎片栓塞可导致中风,影响生存和生活质量。脑栓塞保护装置(cepd)在降低卒中风险中的作用仍存在争议。我们的目的是评估cepd对TAVI后卒中风险和神经认知结果的影响。方法:检索PubMed、Scopus、Web of Science、Cochrane、Embase、Ovid等6个数据库,检索截止日期为2023年1月20日。原始随机对照试验(rct)仅纳入并使用Cochrane偏倚风险(ROB)工具进行严格评价。结果:共分析了7项rct(4091例)。cepd显著降低tavi后2-5天内致残性卒中的风险(相对风险= 0.455,95% CI: [0.214, 0.967];p = 0.041)。然而,在30天的随访中,两组的致残性卒中风险无显著差异(相对风险= 1.295,95% CI: [0.373, 4.493];p = 0.684)。在2-5天、30天或90天的非致残性或总体卒中发生率方面没有观察到显著差异。此外,cepd对危及生命的出血、主要血管并发症、死亡率或急性肾损伤的风险没有显著影响。结论:与未使用cepd相比,cepd可有效降低tavi后(2-5天)的致残性卒中风险,但对30天后非致残性卒中、总体卒中或致残性卒中的发生率无显著影响。这些发现表明,cepd可能提供短期的神经保护。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cerebral embolic protection in transcatheter aortic valve implantation (TAVI): a pooled analysis of 4091 patients.

Background: Transcatheter aortic valve implantation (TAVI) is increasingly used for severe aortic stenosis, but debris embolization during the procedure can lead to strokes, impacting survival and quality of life. The role of cerebral embolic protection devices (CEPDs) in mitigating stroke risk remains debated. We aim to evaluate the impact of CEPDs on the risk of stroke and neurocognitive outcomes after TAVI.

Methods: Six databases (PubMed, Scopus, Web of Science, Cochrane, Embase, and Ovid) were searched until 20 January 2023. Original randomized controlled trials (RCTs) were only included and critically appraised using the Cochrane risk of bias (ROB) tool.

Results: Seven RCTs (4091 patients) were analyzed. CEPDs significantly reduced the risk of disabling stroke within 2-5 days post-TAVI (relative risk = 0.455, 95% CI: [0.214, 0.967]; p = 0.041). However, there was no significant difference in disabling stroke risk between the two groups at the 30-day follow-up (relative risk = 1.295, 95% CI: [0.373, 4.493]; p = 0.684). No significant differences were observed in non-disabling or overall stroke rates at 2-5 days, 30 days, or 90 days. Additionally, CEPDs did not significantly affect risks of life-threatening bleeding, major vascular complications, mortality, or acute kidney injury.

Conclusion: CEPDs are effective in reducing disabling stroke risk in the immediate post-TAVI period (2-5 days) but did not significantly affect the rates of non-disabling stroke, overall stroke, or disabling stroke after 30 days when compared to non-CEPD use. These findings suggest that CEPDs may offer short-term neuroprotection.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cardiovascular Intervention and Therapeutics
Cardiovascular Intervention and Therapeutics CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
6.30
自引率
12.50%
发文量
68
期刊介绍: Cardiovascular Intervention and Therapeutics (CVIT) is an international journal covering the field of cardiovascular disease and includes cardiac (coronary and noncoronary) and peripheral interventions and therapeutics. Articles are subject to peer review and complete editorial evaluation prior to any decision regarding acceptability. CVIT is an official journal of The Japanese Association of Cardiovascular Intervention and Therapeutics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信